Research supports Kaneka probiotic formulation for infant FGID

21-Apr-2022

Based on the findings of the study, the researchers conclude the formulation can significantly reduce the severity of FGID such as colic and constipation

Kaneka Probiotics has announced the publication of a study examining the effects of a formulation of two probiotic strains on functional gastrointestinal disorders (FGID). The formulation, which consisted of Bifidobacterium longum KABP-042 and Pediococcus pentosaceus KABP-041 strains, was also evaluated for its safety and mechanisms of action in the GI system including intestinal barrier integrity.

Based on the findings of the study, the researchers conclude the formulation can significantly reduce the severity of FGID such as colic and constipation. In addition to its effect on the infants themselves, the researchers say, parents experienced favourable results for anxiety. Scientists estimate that one in two infants develop FGID during the first 6 months of life, and the most prevalent manifestations of FGID are infant colic and functional constipation. The microbiota of infants with FGID are altered and contribute to the condition characterised as a gut-brain axis disorder, Kaneka says.

The study, published in Frontier of Microbiology, examined 34 infants, who were administered the liquid probiotic drops for 14 weeks. The university researchers from Spain and Pediatric Primary Care in Italy conclude the formulation reduced FGID severity and was also safe and tolerable. The researchers evaluated the formulation across infants of different feeding modes (breast-fed as well as formula-fed), as well as different delivery types (vaginally delivered or C-section). The aforementioned FGID benefits were reportedly observed regardless of the feeding or delivery mode.

Sign up for your free email newsletter

“This newly published study substantiates the efficacy of the KABP Formulation for reducing FGIDs - - which is one of the most prevalent challenges for infants and a significant source of anxiety for parents. Moreover, the study substantiates the efficacy of Floradapt Baby Colic, our dietary supplement probiotic that is constituted entirely of the KABP Formulation,” said Mike Kolifrath, VP, Sales and Marketing of the Probiotics Division at Kaneka. “Although Baby Colic is a dietary supplement and is not intended to diagnose, treat, cure or prevent any disease, this multi-pronged study of the effects of the KABP Formulation adds another layer of support to the existing competent and reliable scientific evidence that Baby Colic supports a calm gut and healthy microflora in babies and helps reduce the duration of crying episodes and crying time. Kaneka’s robust presence in infant probiotic nutrition has again been proven.”

Companies